Carbomimetics

CarboMimetics is a biopharmaceutical start-up company dedicated to the Discovery and Early Development of Original Medicines from Innovative Glycochemistry to treat areas of high unmet medical need. CarboMimetics has developed and exploits a unique & proprietary integrated platform -GlycoSMART- devoted to Rationale/Smart Design, De novo Synthesis and Optimization of Sugar based Drugs (Therapeutic Oligosaccharides). CarboMimetics is developing high-quality, differentiated programmes that seek to provide the Company with the opportunity of maximising their therapeutic and commercial potential for the benefit of patients. Two programs in Oncology show already promising results for inhibition of metastasis and coagulation. Founded in 2013 by Dr Ahmed El Hadri (Chief Executive & Scientific Officer), CarboMimetics expertise lies on an exclusive know-how of more than 18 years strengthened with an experienced and balanced scientific and strategic advisory board.